If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 151 - 160 of 296
A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy
Objective
Study comparing new treatments for newly diagnosed AML with IDH2 gene change
Protocol No
SWOG-MM1OA-S03
Categories
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Objective
Study of IMVT-1402 Treatment in Adult Participants with CIDP
Protocol No
NEURO-IMVT-1402-2401
Evaluating Efficacy When Transitioning From a Current Disease Modifying Therapy DMT to Ublituximab -ENHANCE
Objective
Efficacy Transitioning from a Current DMT to Ublituximab
Protocol No
NEURO-TG-ENHANCE
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-Directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Len
Objective
A Phase 3 Study of BMS-986393 in Adult Patients with RR or RRMM
Protocol No
BMS-CA0881007
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Objective
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in
Advanced KRAS Mutated Cholangiocarcinoma
Advanced KRAS Mutated Cholangiocarcinoma
Protocol No
GENFIT-GNS561-222-1
Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged
Objective
A Phase III study comparing the use investigational drug ziftomenib to intensive chemotherapy and and the use of ziftomenib as maintenance therapy following intensive chemotherapy.
Protocol No
KURA-KO-MEN-017
Categories
Frontline T-Cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification Therapy in Multiple Myeloma
Objective
Study of t-cell engager vs. stem cell transplant and MRD-guided therapy in multiple myeloma
Protocol No
SCRI-FASTER-MM195
Categories
A Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Paltusotine in Adults With Carcinoid Syndrome Due to Well-Differentiated Neuroendocrine Tumors
Objective
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Protocol No
CRINETICS-CRN00808-12
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Objective
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Protocol No
STEMLINE-MEN2312-01
Categories
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for
Objective
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/​or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Protocol No
NEOGENE-NT-175-201